Ozonized autohemotransfusion improves hemorheological parameters and oxygen delivery to tissues in patients with peripheral occlusive arterial disease

Ann Hematol. 2001 Dec;80(12):745-8. doi: 10.1007/s002770100377. Epub 2001 Oct 13.


Twenty-seven subjects suffering from peripheral occlusive arterial disease (POAD, clinical stage II-III according to Fontaine) were enrolled in this study to evaluate the effect of oxygen-ozone therapy upon hemorheological parameters and hemoglobin-oxygen affinity in patients with POAD. All patients underwent a major ozonized autohemotransfusion consisting of the slow reinfusion of 100 ml of autologous blood, previously exposed to a O(2)-O(3) mixture in a glass box for 10 min. Whole blood viscosity, erythrocyte filterability, hematocrit, and fibrinogen levels were assessed at the basal time and 30 min after the reinfusion of ozonized blood. At the same time p50 standard (p50std) values (an indicator of hemoglobin-oxygen affinity) and plasma values of malonyl dialdehyde (MDA, an indicator of lipid peroxidation) were evaluated. At the baseline, patients had significantly higher ( p<0.05- p<0.001) whole blood viscosity, MDA, and p50std values and significantly lower blood filterability ( p<0.01) as compared with 20 matched healthy volunteers (controls). Thirty minutes after the end of a major autohemotransfusion, whole blood viscosity significantly decreased ( p<0.01). This was accompanied by a significant fall in plasma fibrinogen level ( p<0.01) with no change in hematocrit. Blood filterability, MDA plasma level, and p50std values increased significantly at the same time ( p<0.01- p<0.005). The 2,3-DPG value did not change significantly. No significant changes occurred when the same patients received a non-ozonized autohemotransfusion (control test). In conclusion, ozonized autohemotransfusion may be useful to improve both the poor rheological properties of the blood and the oxygen delivery to tissues in patients suffering from POAD.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial

MeSH terms

  • 2,3-Diphosphoglycerate / blood
  • Aged
  • Arterial Occlusive Diseases / blood
  • Arterial Occlusive Diseases / therapy*
  • Blood Transfusion, Autologous*
  • Blood Viscosity
  • Erythrocyte Deformability
  • Female
  • Fibrinogen / analysis
  • Hemoglobins / metabolism
  • Hemorheology*
  • Humans
  • Lipid Peroxidation
  • Male
  • Malondialdehyde
  • Middle Aged
  • Oxygen / blood
  • Oxygen Consumption*
  • Ozone*


  • Hemoglobins
  • 2,3-Diphosphoglycerate
  • Malondialdehyde
  • Ozone
  • Fibrinogen
  • Oxygen